Literature DB >> 15632383

Vioxx: lessons for Health Canada and the FDA.

.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15632383      PMCID： PMC543919          DOI： 10.1503/cmaj.045206

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.

Authors:  Andreas Laupacis; J Michael Paterson; Muhammad Mamdani; Alaa Rostom; Geoffrey M Anderson
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

Review 2.  Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat.

Authors:  Alexandra Barratt; Peter C Wyer; Rose Hatala; Thomas McGinn; Antonio L Dans; Sheri Keitz; Virginia Moyer; Gordon Guyatt For
Journal:  CMAJ       Date:  2004-08-17       Impact factor: 8.262

3.  Rofecoxib (Vioxx) voluntarily withdrawn from market.

Authors:  Barbara Sibbald
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

4.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321
  4 in total
  6 in total

1.  Perspectives on drug withdrawals.

Authors:  Russell Williams
Journal:  CMAJ       Date:  2005-07-19       Impact factor: 8.262

2.  Perspectives on drug withdrawals.

Authors:  David Rapoport
Journal:  CMAJ       Date:  2005-07-19       Impact factor: 8.262

3.  Perspectives on drug withdrawals.

Authors:  Diane C Gorman
Journal:  CMAJ       Date:  2005-07-19       Impact factor: 8.262

4.  Drug safety and regulation.

Authors:  Patrick C Waller; Stephen J W Evans; Keith Beard
Journal:  BMJ       Date:  2005-07-02

5.  Drug safety information through the internet: the experience of an Italian website.

Authors:  Giovanni Polimeni; Alessandra Russo; Maria Antonietta Catania; Andrea Aiello; Alessandro Oteri; Gianluca Trifirò; Gioacchino Calapai; Lidia Sautebin; Massimo Iacobelli; Achille P Caputi
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network.

Authors:  Lorraine E Ferris; Trudo Lemmens
Journal:  Open Med       Date:  2010-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.